/

Other

/

Novo Nordisk Canada Inc.

Novo Nordisk Canada Inc.

Novo Nordisk Canada Inc.

Verified Nov 2026

Other

·

Bagsvaerd, Capital Region of Denmark

·

Since 1923

Novo Nordisk is a global healthcare company founded in 1923 and headquartered in Bagsværd, Denmark. It employs 50,000–100,000 people and generates over $10 billion in annual revenue. The company develops biological medicines for diabetes, obesity, hemophilia, and other chronic diseases across 170 countries. In 2026, Novo Nordisk Canada partnered with Rexall Pharmacy to provide home delivery services for obesity and diabetes medications.

Novo Nordisk Canada Inc.

Verified Nov 2026

AT A GLANCE

Founded

1923

Headquarters

Bagsvaerd, Capital Region of Denmark

Employees

50,000-100,000

Ownership

Novo Nordisk Canada Inc. at a glance

Revenue

$10B+

Est. band

Employees

50,000-100,000

Founded

1923

Headquarters

Bagsvaerd, Capital Region of Denmark

Import activity

7389

Industries

Automotive

Electric Vehicles

Medical

Renewable Energy

Industrial Equipment

Sourcing and import activity

From US customs bill-of-lading records

US sea imports

7389

Named foreign suppliers

50

Top origins

Germany · Netherlands · China · Malaysia

Chart of the supplier's US import shipment volume trend over time

Shared foreign counterparties do not establish that these companies buy from Novo Nordisk Canada Inc..

What this tells a buyer

The company received 7,389 recorded shipments, with primary inbound sourcing from Denmark, Germany, Netherlands, China, Malaysia, and Belgium, drawing on suppliers across 24 countries including Japan, Taiwan, and Brazil.

Novo Nordisk manufactures insulins, GLP-1 receptor agonists, oral anti-diabetics, obesity treatments, hemophilia therapies, and growth hormone products, supported by investments in next-generation biologics and digital health tools.

The company operates as a private entity with over 69,000 employees worldwide and maintains a dual-division structure focused on Diabetes and Obesity Care alongside Biopharmaceuticals.

Source: US customs bill-of-lading records and public filings · Last verified Nov 13, 2026

STABILITY SIGNALS

Established & active

103 years in operation (founded 1923).

7,389 US import shipments on record.

Overview

Novo Nordisk is a global healthcare company founded in 1923 and headquartered in Bagsværd, Denmark. It employs 50,000–100,000 people and generates over $10 billion in annual revenue. The company develops biological medicines for diabetes, obesity, hemophilia, and other chronic diseases across 170 countries. In 2026, Novo Nordisk Canada partnered with Rexall Pharmacy to provide home delivery services for obesity and diabetes medications.

At a glance

Attribute

Detail

Founded

1923

Headquarters

Bagsvaerd, Capital Region of Denmark

Employees

50,000-100,000

Revenue

$10B+ (estimated)

What Novo Nordisk Canada Inc. makes

Novo Nordisk manufactures insulins, GLP-1 receptor agonists, oral anti-diabetics, obesity treatments, hemophilia therapies, and growth hormone products, supported by investments in next-generation biologics and digital health tools.

Trade and customs footprint

The company received 7,389 recorded shipments, with primary inbound sourcing from Denmark, Germany, Netherlands, China, Malaysia, and Belgium, drawing on suppliers across 24 countries including Japan, Taiwan, and Brazil. US customs bill-of-lading records list 7389 inbound shipments across 50 foreign suppliers, with top origins including Germany · Netherlands · China · Malaysia.

Latest developments

Company details

The company operates as a private entity with over 69,000 employees worldwide and maintains a dual-division structure focused on Diabetes and Obesity Care alongside Biopharmaceuticals. Novo Nordisk Canada Inc. was founded in 1923, has an estimated 50,000-100,000 employees, and is headquartered in Bagsvaerd, Capital Region of Denmark. On the LightSource stability read it is rated "Established & active": 103 years in operation (founded 1923). 7,389 US import shipments on record.

Frequently asked questions

What does Novo Nordisk Canada Inc. do?

Novo Nordisk is a global healthcare company founded in 1923 and headquartered in Bagsværd, Denmark. It employs 50,000–100,000 people and generates over $10 billion in annual revenue. The company develops biological medicines for diabetes, obesity, hemophilia, and other chronic diseases across 170 countries. In 2026, Novo Nordisk Canada partnered with Rexall Pharmacy to provide home delivery services for obesity and diabetes medications.

Where is Novo Nordisk Canada Inc. headquartered?

Novo Nordisk Canada Inc. is headquartered in Bagsvaerd, Capital Region of Denmark.

When was Novo Nordisk Canada Inc. founded?

Novo Nordisk Canada Inc. was founded in 1923.

How big is Novo Nordisk Canada Inc.?

Novo Nordisk Canada Inc. has an estimated 50,000-100,000 employees, with revenue in the $10B+ range (estimated).

Does Novo Nordisk Canada Inc. import from overseas suppliers?

US customs bill-of-lading records show 7389 inbound shipments for Novo Nordisk Canada Inc., with top origins including Germany · Netherlands · China · Malaysia.

Related suppliers

Explore other suppliers in the LightSource directory:

Last verified Nov 2026. Is this your company? Request a correction.

Location & contact

Bagsvaerd, Capital Region of Denmark (HQ)Headquarters · Denmark
Bagsvaerd, Capital Region of Denmark (HQ)Bagsvaerd, Capital Region of Denmark, 2880, DenmarkHeadquarters

Evaluating suppliers like these?

This profile is part of a public-data sample of the full LightSource directory. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.